A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study is a Phase 2a/b, randomized, double‐blind, placebo‐controlled, multicentertrial designed to evaluate the efficacy, safety, tolerability and dose‐responserelationship of DDY391 in participants with active moderate to severe PsA.The study is composed of two sequential parts: ‐ Part A to evaluate efficacy, safety and tolerability of DDY391 compared withplacebo. ‐ Part B to determine the dose‐response relationship of multiple doses of DDY391compared with placebo.
Epistemonikos ID: 0f8fefc3875c0332b9e23d52d88a6e1655be8562
First added on: Sep 03, 2026